The stimulus of gravity affects RNA production, which helps maintain the strength of human muscles on Earth (top), as seen in this section of muscle fiber taken from an astronaut before spaceflight. Astronauts in orbit and patients on Earth fighting muscle-wasting diseases need countermeasures to prevent muscle atrophy, indicated here with white lipid droplets (bottom) in the muscle sample taken from the same astronaut after spaceflight. Kerneth Baldwin of the University of California, Irvine, is conducting research on how reducing the stimulus of gravity affects production of the RNA that the body uses as a blueprint for making muscle proteins. Muscle proteins are what give muscles their strength, so when the RNA blueprints aren't available for producing new proteins to replace old ones -- a situation that occurs in microgravity -- the muscles atrophy. When the skeletal muscle system is exposed to microgravity during spaceflight, the muscles undergo a reduced mass that translates to a reduction in strength. When this happens, muscle endurance decreases and the muscles are more prone to injury, so individuals could have problems in performing extravehicular activity [space walks] or emergency egress because their bodies are functionally compromised.

iss052e018939 (7/24/2017) --- NASA astronaut Peggy Whitson working with the Efficacy and Metabolism of Azonafide Antibody-Drug Conjugates in Microgravity (ADCs in Microgravity). The ADCs in Microgravity investigation evaluates new antibody-drug conjugates that combine an immune-activating drug with antibodies in order to target only cancer cells, increasing the effectiveness of chemotherapy and reducing its side effects. In microgravity, cancer cells grow in three-dimensional, spheroid structures that closely resemble their form in the human body, allowing for better drug testing. This investigation may accelerate development of targeted therapies for cancer patients.

iss052e018944 (7/24/2017) --- NASA astronaut Peggy Whitson working with the Efficacy and Metabolism of Azonafide Antibody-Drug Conjugates in Microgravity (ADCs in Microgravity). The ADCs in Microgravity investigation evaluates new antibody-drug conjugates that combine an immune-activating drug with antibodies in order to target only cancer cells, increasing the effectiveness of chemotherapy and reducing its side effects. In microgravity, cancer cells grow in three-dimensional, spheroid structures that closely resemble their form in the human body, allowing for better drug testing. This investigation may accelerate development of targeted therapies for cancer patients.

Astronaut Chiaki Mukai conducts the Lower Body Negative Pressure (LBNP) experiment inside the International Microgravity Laboratory-2 (IML-2) mission science module. Dr. Chiaki Mukai is one of the National Space Development Agency of Japan (NASDA) astronauts chosen by NASA as a payload specialist (PS). She was the second NASDA PS who flew aboard the Space Shuttle, and was the first female astronaut in Asia. When humans go into space, the lack of gravity causes many changes in the body. One change is that fluids normally kept in the lower body by gravity shift upward to the head and chest. This is why astronauts' faces appear chubby or puffy. The change in fluid volume also affects the heart. The reduced fluid volume means that there is less blood to circulate through the body. Crewmembers may experience reduced blood flow to the brain when returning to Earth. This leads to fainting or near-fainting episodes. With the use of the LBNP to simulate the pull of gravity in conjunction with fluids, salt tablets can recondition the cardiovascular system. This treatment, called "soak," is effective up to 24 hours. The LBNP uses a three-layer collapsible cylinder that seals around the crewmember's waist which simulates the effects of gravity and helps pull fluids into the lower body. The data collected will be analyzed to determine physiological changes in the crewmembers and effectiveness of the treatment. The IML-2 was the second in a series of Spacelab flights designed by the international science community to conduct research in a microgravity environment Managed by the Marshall Space Flight Center, the IML-2 was launched on July 8, 1994 aboard the STS-65 Space Shuttle Orbiter Columbia mission.

The first United States Microgravity Laboratory (USML-1) flew in orbit inside the Spacelab science module for extended periods, providing scientists and researchers greater opportunities for research in materials science, fluid dynamics, biotechnology (crystal growth), and combustion science. In this photograph, Astronaut Bornie Dunbar and Astronaut Larry DeLucas are conducting the Lower Body Negative Pressure (LBNP) experiment, which is to protect the health and safety of the crew and to shorten the time required to readapt to gravity when they return to Earth. When humans go into space, the lack of gravity causes many changes in the body. One change is that fluids normally kept in the lower body by gravity, shift upward to the head and chest. This is why astronauts' faces appear chubby or puffy. The change in fluid volume also affects the heart. The reduced fluid volume means that there is less blood to circulate through the body. Crewmembers may experience reduced blood flow to the brain when returning to Earth. This leads to fainting or near-fainting episodes. With the use of LBNP to simulate the pull of gravity in conjunction with fluids, salt tablets can recondition the cardiovascular system. This treatment, called "soak," is effective up to 24 hours. The LBNP uses a three-layer collapsible cylinder that seals around the crewmember's waist which simulates the effects of gravity and helps pull fluids into the lower body. The data collected will be analyzed to determine physiological changes in the crewmembers and effectiveness of the treatment. The USML-1 was launched aboard the Space Shuttle Orbiter Columbia (STS-50) on June 25, 1992.

Proteins are the building blocks of our bodies and the living world around us. Within our bodies proteins make it possible for red blood cells to carry oxygen throughout the body. Others help transmit nerve impulses so we can hear, smell and feel the world around us. While others play a crucial role in preventing or causing disease. If the structure of a protein is known, then companies can develop new or improved drugs to fight the disease of which the protein is a part. To determine protein structure, researchers must grow near-perfect crystals of the protein. On Earth convection currents, sedimentation and other gravity-induced phenomena hamper crystal growth efforts. In microgravity researchers can grow near-perfect crystals in an environment free of these effects. Because of the enormous potential for new pharmaceutical products the Center for Macromolecular Crystallography--the NASA Commercial Space Center responsible for commercial protein crystal growth efforts has more than fifty major industry and academic partners. Research on crystals of human insulin could lead to improved treatments for diabetes.

Astronaut David C. Hilmers conducts the Microgravity Vestibular Investigations (MVI) sitting in its rotator chair inside the IML-1 science module. When environmental conditions change so that the body receives new stimuli, the nervous system responds by interpreting the incoming sensory information differently. In space, the free-fall environment of an orbiting spacecraft requires that the body adapts to the virtual absence of gravity. Early in flights, crewmembers may feel disoriented or experience space motion sickness. MVI examined the effects of orbital flight on the human orientation system to obtain a better understanding of the mechanisms of adaptation to weightlessness. By provoking interactions among the vestibular, visual, and proprioceptive systems and then measuring the perceptual and sensorimotor reactions, scientists can study changes that are integral to the adaptive process. The IML-1 mission was the first in a series of Shuttle flights dedicated to fundamental materials and life sciences research with the international partners. The participating space agencies included: NASA, the 14-nation European Space Agency (ESA), the Canadian Space Agency (CSA), the French National Center of Space Studies (CNES), the German Space Agency and the German Aerospace Research Establishment (DAR/DLR), and the National Space Development Agency of Japan (NASDA). Both life and materials sciences benefited from the extended periods of microgravity available inside the Spacelab science module in the cargo bay of the Space Shuttle Orbiter. Managed by the Marshall Space Flight Center, IML-1 was launched on January 22, 1992 aboard the Space Shuttle Orbiter Discovery (STS-42 mission).